18F-FDG PET/CT预测和诊断食管癌新辅助放化疗后间期转移
研究纳入2006至2015年间783例可切除食管癌患者,分析新辅助放化疗前后18F-FDG PET/CT对间期转移的诊断效能并建立预测评分。65例(8.3%)发现间期转移,敏感度74.7%、特异度93.7%;肿瘤长度、cN状态、鳞癌组织学及基线SUVmax与间期转移相关,预测评分乐观校正C指数为0.67。
要点
- 18F-FDG PET/CT再分期诊断间期转移的敏感度74.7%、特异度93.7%。
- 783例中65例(8.3%)发现间期转移,44例(5.6%)为假阳性病灶。
- 肿瘤长度、cN状态、鳞癌组织学及基线SUVmax与间期转移相关,预测评分C指数0.67。
核心结论
- 18F-FDG PET/CT再分期在食管癌放化疗后8.3%的患者中检出远处间期转移。
- 所建立的预测评分可能对间期转移风险进行分层,并可用于对最可能获益的患者优先安排其他再分期检查。
研究设计与样本
- 研究从前瞻性维护的数据库中分析2006至2015年间783例连续的可切除食管癌患者,均接受放化疗及治疗前后18F-FDG PET/CT。
- 以组织学验证或临床随访为参考标准,按患者计算诊断准确性指标。
- 采用多变量logistic回归分析确定间期转移的治疗前预测因素,并建立预测评分。
主要发现
- 783例接受18F-FDG PET/CT再分期的患者中,65例(8.3%)发现间期转移,44例(5.6%)判定为假阳性病灶。
- 敏感度为74.7%(95%CI:64.3-83.4%),特异度为93.7%(95%CI:91.6-95.4%)。
- 多变量分析显示肿瘤长度、cN状态、鳞癌组织学及基线SUVmax与间期转移相关。
- 基于上述标准建立的预测评分乐观校正C指数为0.67,校准良好。
关键数值与推荐
- 敏感度74.7%(95%CI:64.3-83.4%),特异度93.7%(95%CI:91.6-95.4%)。
- 预测评分乐观校正C指数为0.67。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: During neoadjuvant chemoradiotherapy for oesophageal cancer, or in the interval prior to surgery, some patients develop systemic metastasis. This study aimed to evaluate the diagnostic performance of 18F-FDG PET/CT for the detection of interval metastasis and to identify predictors of interval metastases in a large cohort of oesophageal cancer patients. METHODS: In total, 783 consecutive patients with potentially resectable oesophageal cancer who underwent chemoradiotherapy and pre- and post-treatment 18F-FDG PET/CT between 2006 and 2015 were analyzed from a prospectively maintained database. Diagnostic accuracy measures were calculated on a per-patient basis using histological verification or clinical follow-up as a reference standard. Multivariable logistic regression analysis was performed to determine pre-treatment predictors of interval metastasis. A prediction score was developed to predict the probability of interval metastasis. RESULTS: Of 783 patients that underwent 18F-FDG PET/CT restaging, 65 (8.3%) were found to have interval metastasis and 44 (5.6%) were deemed to have false positive lesions. The resulting sensitivity and specificity was 74.7% (95% CI: 64.3-83.4%) and 93.7% (95% CI: 91.6-95.4%), respectively. Multivariable analysis revealed that tumor length, cN status, squamous cell tumor histology, and baseline SUVmax were associated with interval metastasis. Based on these criteria, a prediction score was developed with an optimism adjusted C-index of 0.67 that demonstrated accurate calibration. CONCLUSIONS: 18F-FDG PET/CT restaging detects distant interval metastases in 8.3% of patients after chemoradiotherapy for oesophageal cancer. The provided prediction score may stratify risk of developing interval metastasis, and could be used to prioritize additional restaging modalities for patients most likely to benefit.
引用
- Goense L, Ruurda JP, Carter BW, et al. Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2018. PMID: 29663014. doi:10.1007/s00259-018-4011-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。